On the biochemical background of cimetidine's anti-ulcerogenic effect in the rat.
It was published earlier that during gastric ulceration an elevation in the antral and fundic mucosal cAMP/cGMP ratios can be encountered in rats. This phenomenon was interpreted as a probable sign of the reparative, antiulcerogenic processes. This assumption received further evidence when the experimental animals were treated with prostacyclin. According to the present investigations the H2-receptor blocker cimetidine, in such small dose which does not interfere with the gastric acid secretion, evoked the same cAMP/cGMP ratio elevating effect. On the basis of the performed investigations the questions raised, namely: Does the cytoprotective (anti-ulcerogenic) effect of different drugs have a common molecular basis in the (rat) gastric mucosa? If so, what is the possible role of the mucosal cyclic nucleotides in this process? Further studies are being needed in this field to clarify all details.
Bálint
G A
GA
Department of Pharmacology, Addis Ababa University, Ethiopia.
D000704:Analysis of Variance; D000818:Animals; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005748:Gastric Fundus / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism*; D011706:Pyloric Antrum / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000378:metabolism
D002927:Cimetidine; D011464:Epoprostenol; D000242:Cyclic AMP; D006152:Cyclic GMP